Tested batch: EP-260529-GH100
GHK-Cu (Copper Peptide) is a tripeptide with copper ion (Pickart et al., 2015). Each box contains 10 vials of lyophilized powder, with 100mg per vial. This peptide is supplied as a research compound for laboratory use only.
Specifications: SKU CU10 · 10 vials of lyophilised powder per box · 100mg per vial · measured net content 106.11 mg. Testing: four Kovera Labs reports for batch EP-260529-GH100: RP-HPLC purity 99.269% with LC-MS identity, endotoxin < 0.20 EU/mL, heavy metals and sterility – see the certificates below. Further reading: GHK-Cu in Australia: product overview, GHK-Cu copper peptides overview and GHK-Cu: a research guide to evaluating suppliers. For laboratory research use only; not for human consumption.
Free shipping on all products.
This product is strictly intended for laboratory research use only. Not for human consumption. All products sold are for research purposes and should only be handled by qualified professionals in a controlled laboratory environment.
Tested batch: EP-260529-GH100 · 4 published certificates. Report library updated .
Batch EP-260529-GH100 – four Kovera Labs reports. Purity and identity: RP-HPLC purity 99.269%, net content 106.11 mg, LC-MS identity: GHK-Cu (KVR-2026-C63CFA, 29 June 2026). Endotoxin: < 0.20 EU/mL (ENDO-KVR-2026-C63CFA). Heavy metals: lead < 0.5, arsenic < 0.15, cadmium < 0.05 and mercury < 0.3 ppm (HM-KVR-2026-C63CFA). Sterility: no bacterial growth (aerobic and anaerobic) and no fungi or yeast detected after a 2-day incubation (RSTER-KVR-2026-C63CFA). Each certificate links to its Kovera Labs verification record, and the product image shows the same batch reference. For laboratory research use only.
| Test | Reported result | Report ID | Report date |
|---|---|---|---|
| Purity and Identity (COA) | Purity: 99.269 %; Net content: 106.11 mg; Identity confirmation: GHK-Cu | KVR-2026-C63CFA | 29 June 2026 |
| Endotoxin | Endotoxin: < 0.20 EU/mL | ENDO-KVR-2026-C63CFA | 30 May 2026 |
| Heavy Metals | Lead: < 0.5 ppm; Arsenic: < 0.15 ppm; Cadmium: < 0.05 ppm; Mercury: < 0.3 ppm | HM-KVR-2026-C63CFA | 31 May 2026 |
| Sterility testing | Bacteria (aerobic/anaerobic): No microbial growth detected; Fungi / yeast: Not Detected; Incubation period: 2 days | RSTER-KVR-2026-C63CFA | 30 May 2026 |
Read how to interpret and verify a Kovera Labs report or browse our testing standards and report directory.
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Purity | 99.269 % | — | RP-HPLC |
| Net content | 106.11 mg | — | — |
| Identity confirmation | GHK-Cu | — | LC-MS |
| Endotoxin screen | Pass | — | — |
| Microbial sterility screen | No Growth | — | — |
| Arsenic (As) screening | < 0.15 | — | — |
| Cadmium (Cd) screening | < 0.05 | — | — |
| Lead (Pb) screening | < 0.5 | — | — |
| Mercury (Hg) screening | < 0.3 | — | — |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Endotoxin | < 0.20 EU/mL | ≤ 0.5 | — |
| Final determination | PASS | — | — |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Lead | < 0.5 ppm | ≤ 10 | ICP-MS |
| Arsenic | < 0.15 ppm | ≤ 1.5 | ICP-MS |
| Cadmium | < 0.05 ppm | ≤ 0.5 | ICP-MS |
| Mercury | < 0.3 ppm | ≤ 3 | ICP-MS |
Verify this certificate on Kovera Labs
| Reported test | Result | Stated criterion | Method, where stated |
|---|---|---|---|
| Bacteria (aerobic/anaerobic) | No microbial growth detected | — | — |
| Fungi / yeast | Not Detected | — | — |
| Incubation period | 2 days | — | — |
| Temperature | 30-35C | — | — |
| Final determination | SAMPLE PASSES STERILITY SCREEN | — | — |
Evidence reviews and laboratory guides relevant to GHK-Cu 100mg, plus the testing behind each batch.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK) (Pickart et al., 2015). GHK was first reported in 1973 as a tripeptide in human serum, in work on the survival of cultured liver cells (Pickart & Thaler, 1973). It is present in human plasma, saliva and urine and has a strong affinity for copper(II) (Pickart et al., 2015).
Published GHK-Cu research has mainly used cell culture, animal models and gene-expression data. Reviews from the group that first described the peptide summarise effects reported in those models on extracellular-matrix components such as collagen and glycosaminoglycans, and on gene-expression profiles (Pickart et al., 2015; Pickart & Margolina, 2018). Findings in cell or animal systems do not show the same effects in people.
About the evidence. Findings reported in published studies relate to the materials used in that work. This product is supplied by Eternal Peptides Wholesale for laboratory research use only and is not for human or veterinary use. Its Kovera Labs reports are published on this page and in the COA library.
Further reading: GHK-Cu chemistry and copper binding: evidence review
Explore GHK-Cu research, Australian buying guides and laboratory documentation.
